v3.26.3
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 27, 2026
Sep. 28, 2025
Sep. 27, 2026
Sep. 28, 2025
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     $ 1,910  
Provision [2] $ 753 $ 237 1,221 $ 784
Utilization and other [3]     (934)  
Balance, ending [4] 2,197   2,197  
Balance Sheet Location [Axis]: us-gaap:OtherLiabilitiesCurrent        
Restructuring Reserve [Roll Forward]        
Balance, beginning     1,400  
Balance, ending 1,200   1,200  
Balance Sheet Location [Axis]: us-gaap:OtherLiabilitiesNoncurrent        
Restructuring Reserve [Roll Forward]        
Balance, beginning     466  
Balance, ending 972   972  
Employee Termination Costs [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     1,783  
Provision     1,071  
Utilization and other [3]     (758)  
Balance, ending [4] 2,096   2,096  
Asset Impairment Charges [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     0  
Provision     112  
Utilization and other [3]     (112)  
Balance, ending [4] 0   0  
Exit Costs [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     127  
Provision     38  
Utilization and other [3]     (63)  
Balance, ending [4] $ 101   $ 101  
[1] Included in Other current liabilities ($1.4 billion) and Other noncurrent liabilities ($466 million).
[2] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $461 million for the three months ended September 27, 2026 (including charges of $385 million for our Realigning our Cost Base Program and charges of $65 million for our Manufacturing Optimization Program), (ii) charges of $882 million for the nine months ended September 27, 2026 (including charges of $849 million for our Realigning our Cost Base Program and charges of $14 million for our Manufacturing Optimization Program), (iii) charges of $240 million for the three months ended September 28, 2025 (including charges of $117 million for our Manufacturing Optimization Program and charges of $107 million for our Realigning our Cost Base Program) and (iv) charges of $451 million for the nine months ended September 28, 2025 (including charges of $669 million for our Realigning our Cost Base Program and credits of $295 million for our Manufacturing Optimization Program). For the nine months ended September 28, 2025, Employee terminations included revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.
[3] Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.
[4] Included in Other current liabilities ($1.2 billion) and Other noncurrent liabilities ($972 million).